Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. They currently have $20.00 price target on the stock.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other equities analysts have also recently commented on the company. Leerink Swann set a $27.00 price target on Kura Oncology and gave the stock a buy rating in a report on Saturday, June 15th. ValuEngine raised Kura Oncology from a buy rating to a strong-buy rating in a report on Monday, June 17th. Wedbush set a $30.00 price target on Kura Oncology and gave the stock a positive rating in a report on Monday, June 17th. HC Wainwright reissued a buy rating and set a $29.00 price target on shares of Kura Oncology in a report on Friday, August 2nd. Finally, BidaskClub cut Kura Oncology from a buy rating to a hold rating in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $27.89.

Kura Oncology stock opened at $15.81 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 23.50 and a current ratio of 23.50. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $21.42. The stock has a market capitalization of $734.74 million, a P/E ratio of -9.19 and a beta of 2.51. The stock has a fifty day moving average of $19.12 and a 200-day moving average of $16.93.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. On average, research analysts forecast that Kura Oncology will post -1.61 earnings per share for the current year.

In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total value of $379,980.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc increased its holdings in Kura Oncology by 21.7% in the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after purchasing an additional 923 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in Kura Oncology by 164.9% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after purchasing an additional 1,204 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in Kura Oncology in the 2nd quarter worth about $25,000. Wells Fargo & Company MN increased its holdings in Kura Oncology by 3.3% in the 2nd quarter. Wells Fargo & Company MN now owns 42,448 shares of the company’s stock worth $835,000 after purchasing an additional 1,346 shares in the last quarter. Finally, CWM LLC acquired a new position in Kura Oncology in the 1st quarter worth about $25,000. 79.65% of the stock is owned by institutional investors and hedge funds.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Why do companies pay special dividends?

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.